EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma

Yong Pan iD, Yiru Zhang, Daiwen Mao, Zhou Fang, Yingqiu Ma, Danwen Jin, Shibo Li

ACS Omega · 19.11.2024 · 9 (46) · 46492-46504

DOI: 10.1021/acsomega.4c08010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 10.11.2024. Verfasst von Yong Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Major Scientific and Technological Project of Zhejiang Province, Zhejiang Traditional Chinese Medicine Administration.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PDHA1 was associated with metabolic reprogramming in tumor progression. However, the clinical value of PDHA1, especially for prediction of drug sensitivity in hepatocellular carcinoma (HCC), has not been fully investigated. In this study, we found that PDHA1 expression was higher in HCC tissues compared to normal tissues and was correlated with poor prognosis in HCC patients. PDHA1 expression was mainly positively associated with immune cell infiltration using the TIMER, XCell, MCPCOUNTER, CIBERSORT, EPIC, and QUANTISEQ algorithms, which was validated by single-cell RNA-sequencing analysis. We also discovered that PDHA1 expression was correlated with six immune checkpoint-related genes. Univariate and multivariate Cox regression analyses revealed that PDHA1 expression was an independent prognostic indicator for HCC patients, and the nomogram incorporating PDHA1 expression exhibited excellent predictive capacity. Furthermore, PDHA1 expression was positively linked to the sensitivity of 5-fluorouracil, gemcitabine, paclitaxel, and sorafenib, and the molecular docking analysis demonstrated their excellent binding affinity.

Autor:innen und Institutionen

  • Department of Infectious Diseases, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, China.
  • State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
  • Pathological Diagnosis Center, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, China.

ORCID-Profile: Yong Pan

Förderung

  • Major Scientific and Technological Project of Zhejiang Province
  • Zhejiang Traditional Chinese Medicine Administration

Zitieren

APA

Pan, Y., Zhang, Y., Mao, D., Fang, Z., Ma, Y., Jin, D., & Li, S. (2024). Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma. ACS Omega, 9(46), 46492-46504. https://doi.org/10.1021/acsomega.4c08010

Vancouver

Pan Y, Zhang Y, Mao D, Fang Z, Ma Y, Jin D, et al. Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma. ACS Omega. 2024;9(46):46492-46504. doi:10.1021/acsomega.4c08010

BibTeX
@article{Pan2024,
  author = {Pan, Yong and Zhang, Yiru and Mao, Daiwen and Fang, Zhou and Ma, Yingqiu and Jin, Danwen and Li, Shibo},
  title = {Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma},
  journal = {ACS Omega},
  year = {2024},
  volume = {9},
  number = {46},
  pages = {46492--46504},
  doi = {10.1021/acsomega.4c08010}
}
Kostenlos starten →